Paul, Carle

• SKIN The Journal of Cutaneous Medicine Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
  Calcipotriol Plus Betamethasone Dipropionate Foam is Effective in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analysis of the PSO-ABLE Study
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference® - Poster Presentations from FC22 Dermatology Conference®: Psoriasis
  Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®) - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
  Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
  Brodalumab, a Human Anti-Interleukin-17 Receptor A Monoclonal Antibody, Shows Low Immunogenicity in Patients with Moderate-to-Severe Psoriasis
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Poster Presentations from FC21 Dermatology Conference®: Psoriasis
  Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
  Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference® - Posters from 2023 WCH Dermatology Conference: Psoriasis
  Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 7 No. 6 (2023): November 2023 Issue - Poster Presentations from FC23 Dermatology Conference®: Psoriasis
  Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials
  Abstract  PDF
• SKIN The Journal of Cutaneous Medicine Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®) - Poster Presentations from FC21 Dermatology Conference®: Psoriasis
  Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial
  Abstract  Poster PDF
• SKIN The Journal of Cutaneous Medicine Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference® - Poster Presentations from FC22 Dermatology Conference®: Psoriasis
  Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
  Abstract  Poster PDF